Аннотация
Relevance: Small intestinal bacterial overgrowth (SIBO) is a common disorder of the intestinal microbiota that can significantly affect gastrointestinal function, immune response, and metabolism. In patients with colorectal cancer (CRC), the risk of developing SIBO is increased due to anatomical and functional alterations of the intestine, the oncological process itself, surgical interventions, and chemo- and radiotherapy. Despite the growing interest in the role of the gut microbiota in CRC carcinogenesis and disease course, the prevalence, pathogenetic significance, and clinical consequences of SIBO in this patient population remain insufficiently studied.The study aimed to analyze and summarize current literature data on the prevalence, mechanisms of development, diagnostic approaches, and clinical significance of small intestinal bacterial overgrowth in patients with colorectal cancer.Materials and Methods: A review of domestic and international scientif ic publications indexed in PubMed, Scopus, Web of Science, and eLIBRARY was conducted, focusing on SIBO, the intestinal microbiota, and CRC. Original studies, systematic reviews, and meta-analyses published in recent years were included in the analysis.Results: The literature analysis demonstrated a high prevalence of SIBO in patients with CRC, particularly after surgical treatment and during anticancer therapy. SIBO was associated with increased gastrointestinal symptoms, impaired nutritional status, reduced quality of life, and a potential impact on the effectiveness of oncological treatment. Current diagnostic methods and approaches to the management of SIBO are discussed.Conclusion: SIBO is a clinically significant condition in patients with CRC and requires timely diagnosis and a comprehensive treatment approach. Further studies are needed to develop standardized management algorithms for this patient population.